Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the rich diversity of patient and healthcare provider populations. As a result, bringing a pharmaceutical or biotech product to Europe has been, and continues to be, intimidating for most manufacturers. Many manufacturers still believe that the traditional launch model – signing a handful of disjointed partnerships – is the only way to launch a new product […]
Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This conversation takes a closer look at the following topics: How to get past the perceived launch “red tape” in the EU Emerging regulatory, HTA, access, data and commercial routes that will begin to open up this market What a successful post-pandemic launch should look like and determine the steps you need to get there. Investments […]
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains constant is product distribution through parallel trade. In 2012, parallel trade activity rose by up to 25% in some countries; but distributing a product across territories with diverse regulations, cultures and languages is complex. Now, there is an even more efficient way for manufacturers to distribute treatments in Europe. The answer is one end-to-end commercialization […]